Evidence map›Paper›PMID 34281267›Full record

SynthesisInternational journal of molecular sciences2021

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?

Vladimira Vuletić, Valentino Rački, Eliša Papić, Borut Peterlin

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Pharmacogenetics in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Vladimira VuletićClinic of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.
Valentino RačkiClinic of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.ORCID 0000-0003-3246-0506
Eliša PapićClinic of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.
Borut PeterlinClinical Institute of Medical Genetics, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
University of Rijeka · HRLjubljana University Medical Centre · SI

Funding

Hrvatska Zaklada za Znanost IP-2019-04-7276University of Rijeka uniri-biomed-18-1981353
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is the second most frequent neurodegenerative disease, which creates a significant public health burden. There is a challenge for the optimization of therapies since patients not only respond differently to current treatment options but also develop different side effects to the treatment. Genetic variability in the human genome can serve as a biomarker for the metabolism, availability of drugs and stratification of patients for suitable therapies. The goal of this systematic review is to assess the current evidence for the clinical translation of pharmacogenomics in the personalization of treatment for Parkinson's disease.

methodsWe performed a systematic search of Medline database for publications covering the topic of pharmacogenomics and genotype specific mutations in Parkinson's disease treatment, along with a manual search, and finally included a total of 116 publications in the review.

resultsWe analyzed 75 studies and 41 reviews published up to December of 2020. Most research is focused on levodopa pharmacogenomic properties and catechol-O-methyltransferase (COMT) enzymatic pathway polymorphisms, which have potential for clinical implementation due to changes in treatment response and side-effects. Likewise, there is some consistent evidence in the heritability of impulse control disorder via Opioid Receptor Kappa 1 (OPRK1), 5-Hydroxytryptamine Receptor 2A (HTR2a) and Dopa decarboxylase (DDC) genotypes, and hyperhomocysteinemia via the Methylenetetrahydrofolate reductase (MTHFR) gene. On the other hand, many available studies vary in design and methodology and lack in sample size, leading to inconsistent findings.

conclusionsThis systematic review demonstrated that the evidence for implementation of pharmacogenomics in clinical practice is still lacking and that further research needs to be done to enable a more personalized approach to therapy for each patient.

Indexed as

Antiparkinson AgentsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsDopamine AgonistsGenotypeHumansLevodopaMonoamine Oxidase InhibitorsParkinson DiseasePharmacogeneticsPharmacogenomic VariantsTranslational Research, BiomedicalAntiparkinson AgentsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsCOMT protein, humanDopamine AgonistsLevodopaMonoamine Oxidase Inhibitorsclinical implementationdrug responselevodopaParkinson’s diseasepersonalized medicinepharmacogenomics

Identifiers

PMID34281267
PMCPMC8268929
OpenAlexW3178039558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.